These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16122842)

  • 21. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
    Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 27. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on diagnosis and management of essential thrombocythemia.
    Gisslinger H
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):430-6. PubMed ID: 16810619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Dingli D; Tefferi A
    Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
    Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of essential thrombocythemia.
    Gangat N; Tefferi A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1679-85. PubMed ID: 18570601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Essential thrombocythaemia.
    Double G; Harrison C
    Hematology; 2015 Mar; 20(2):119-20. PubMed ID: 25715049
    [No Abstract]   [Full Text] [Related]  

  • 36. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
    Griesshammer M
    Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
    Hernández-Boluda JC; Pereira A; Cervantes F; Gómez M; Arellano-Rodrigo E; Alvarez-Larrán A; Ferrer-Marín F; Kerguelen A; Márquez JA; Antelo ML; Besses C;
    Ann Hematol; 2013 Jun; 92(6):771-5. PubMed ID: 23354997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.